(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 34.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Anaptysbio's revenue in 2024 is $17,157,000.On average, 4 Wall Street analysts forecast ANAB's revenue for 2024 to be $586,834,077, with the lowest ANAB revenue forecast at $321,156,972, and the highest ANAB revenue forecast at $990,233,997. On average, 4 Wall Street analysts forecast ANAB's revenue for 2025 to be $837,952,066, with the lowest ANAB revenue forecast at $321,156,972, and the highest ANAB revenue forecast at $1,445,206,374.
In 2026, ANAB is forecast to generate $1,113,210,354 in revenue, with the lowest revenue forecast at $888,266,658 and the highest revenue forecast at $1,338,154,050.